News and Announcements
Read the latest news from the Division of Hematology/Oncology including awards, publications and announcements.
Patients with advanced-stage melanoma who received immunotherapy both before and after surgery had longer event-free survival than patients who received immunotherapy only after surgery, according to a recent clinical trial published in the New England Journal of Medicine.
Combining a new hormone therapy drug with chemotherapy and another hormone therapy increased overall survival in patients with high-volume and both high-risk and low-risk metastatic hormone-sensitive prostate cancer, according to a post hoc analysis published in the Journal of Clinical Oncology.
A new way to significantly increase the potency of almost any vaccine has been developed by Northwestern scientists.
Targeting cellular post-transcription mechanisms in the CD73 ectoenzyme may promote anti-tumor immunity and slow cancer progression in triple-negative breast cancer, according to a recent Northwestern Medicine study.
Patients with relapsed or refractory hairy cell leukemia who were treated with vemurafenib experienced excellent response and relapse-free survival, according to a recent clinical trial published in Blood.
Patient-reported outcomes in relapsed or refractory large B-cell lymphoma revealed that receiving CAR T-cell immunotherapy was associated with higher quality of life, according to a recent study.
A Northwestern Medicine study has discovered that elevated PALI1 in advanced prostate tumors mediates crosstalk between two primary epigenetic silencing mechanisms, suggesting that dual epigenetic inhibition may be an effective therapeutic strategy.
Investigators have developed a novel personalized T-cell therapy approach that may identify specific targets unique to a patient’s cancer cells more effectively than current treatments, according to findings published in Nature.
Northwestern Medicine scientists have identified a new therapeutic target against tumor cells and developed a compound which slows tumor growth and bolsters immune response.
Twelve faculty with appointments at Feinberg were named to the 2022 “Highly Cited Researchers” list, published by Clarivate Analytics.
Northwestern Medicine investigators have discovered the mechanisms by which a particular protein promotes cancer cell proliferation and survival in acute myeloid leukemia, according to findings published in Blood.
Using machine learning, Northwestern scientists have demonstrated that the protein membrane CD81 interacts with CD44 in promoting tumor cell cluster formation and lung metastasis of triple negative breast cancer.
Northwestern Medicine investigators have discovered that a particular enzyme is essential for regulating cancer cell survival and metastasis under cellular stress, according to a recent study.
More than 480 investigators, students, trainees and faculty presented scientific posters and abstracts at Feinberg’s 16th Annual Lewis Landsberg Research Day.
A two-drug combination has been shown to improve patient response to treatment in relapsed or refractory acute myeloid leukemia.
Investigators have developed a new imaging technique that increases the detection and identification of proteoforms by four-fold when compared to current methods.
A Northwestern Medicine study has identified a molecular mechanism that helps regulate the progression of castration-resistant prostate cancer.
A change in function in a mitochondrial protein is associated with gene expression that may promote the development of cancer, according to a recent Northwestern Medicine Study.
An emerging therapy showed promise in patients with relapsed B-cell lymphoma who are not ideal candidates for stem cell transplants.
An epigenetic inhibitor increased immune system activity in patients with ovarian cancer.
Northwestern Medicine investigators have discovered novel mechanisms that regulate cellular stress response, according to findings published in the Proceedings of the National Academy of Sciences.
Bicarbonate ions are required for cell growth in some cancers, according to a Northwestern Medicine study.
Calcium channel blockers may improve treatment for patients with pancreatic cancer receiving chemotherapy, according to a recent study.
A new androgen biosynthesis inhibitor drug improved progression-free survival in prostate cancer but did not improve overall survival compared to current therapies.
The Cancer Immunology and Immunotherapy Initiative at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University is bringing together Feinberg investigators who study immunotherapy to increase collaboration and accelerate high-impact immunotherapy research.
A blood-based tumor biomarker can predict the benefit of immunotherapy to patients with non-small cell lung cancer.
A transcription factor associated with androgen receptor activity in prostate cancer has a newly discovered role in controlling lipid biosynthesis.
The protein FOXK2 promotes survival of cancer stem cells in ovarian cancer, according to a Northwestern Medicine study.
Northwestern Medicine investigators have discovered a novel signaling pathway activated by interferons, a group of immune system proteins, that suppresses the anti-tumor response of interferons in patients with a particular type of blood cancer, according to findings published in Nature Communications. Targeting this pathway in combination with interferon therapy may provide a novel approach to […]